Would you use consolidation immunotherapy after chemoradiation for patients with stage III NSCLC and EGFR amplification?

The short answer is yes, as long as there is no concurrent oncogenic EGFR mutation. During the early days of EGFR-TKI development over 20 years ago, there were different predictive biomarkers proposed and studied. Pitted against each other were biomarkers using more established pathology methods (EG...